NASDAQ$ANIK
Anika Therapeutics Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported third quarter financial results and raised full-year financial guidance on growing momentum across the business.
Anika Therapeutics reported strong third quarter results with revenue growth exceeding expectations. Joint Preservation and Restoration was up 14% and OA Pain Management was up 2%. The company also raised its overall revenue outlook for fiscal year 2023 to between $164 million and $166 million.
- Delivered 14% growth in Joint Preservation and Restoration.
- Experienced higher-than-expected growth in OA Pain Management.
- Fully launched RevoMotion Reverse Shoulder System.
- Received FDA clearance for Integrity Implant System and X-Twist Fixation System.
Headline financials
Revenue & EPS history
Anika · Revenue · Quarterly
$41.5M
Forward guidance
The Company has raised its overall revenue outlook for fiscal year 2023 to between $164 million and $166 million, representing growth of 5% to 6% compared to 2022, up from its previous range of $159.5 million to $163 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+0.1%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.8%
Avg return
30 days after
51%
33 / 65 earnings
Positive
+32.1%
Q3 2019
Best reaction
-33.0%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -18.8% | -4.7% | -4.8% | |
| Q4 2025 | +16.8% | +31.6% | +30.5% | |
| Q3 2025 | +0.8% | -0.5% | +2.1% | |
| Q1 2025 | -20.7% | -23.2% | -23.0% | |
| Q4 2024 | -11.1% | -7.3% | -20.3% | |
| Q3 2024 | -33.0% | -34.0% | -28.2% | |
| Q2 2024 | -1.0% | -3.6% | -5.4% | |
| Q1 2024 | -10.9% | -9.9% | -9.1% | |
| Q4 2023 | -4.8% | -2.0% | -3.1% | |
| Q3 2023 | +7.4% | +6.7% | +15.2% | |
| Q2 2023 | -4.9% | -12.7% | -18.0% | |
| Q1 2023 | -2.8% | -3.2% | +3.2% | |
| Q4 2022 | -18.0% | -17.4% | -10.4% | |
| Q3 2022 | +0.3% | +5.3% | +6.3% | |
| Q2 2022 | -4.9% | -2.7% | -6.0% | |
| Q1 2022 | -4.9% | -3.8% | +1.1% | |
| Q4 2021 | -15.9% | -18.0% | -20.1% | |
| Q3 2021 | +3.1% | -8.2% | -12.8% | |
| Q2 2021 | +1.0% | +0.8% | +1.3% | |
| Q1 2021 | +1.3% | +2.8% | +10.9% | |
| Q4 2020 | -10.5% | -12.1% | +3.9% | |
| Q3 2020 | -3.3% | +0.2% | +7.6% | |
| Q2 2020 | +0.3% | -8.7% | +2.9% | |
| Q1 2020 | -9.9% | -12.2% | +9.1% | |
| Q4 2019 | +0.4% | +0.1% | -39.5% | |
| Q3 2019 | +32.1% | +21.5% | +3.7% | |
| Q2 2019 | +29.1% | +31.0% | +37.2% | |
| Q1 2019 | +19.6% | +21.5% | +15.9% | |
| Q4 2018 | -15.3% | -18.8% | -26.5% | |
| Q3 2018 | -11.0% | -13.6% | -13.9% | |
| Q2 2018 | +18.6% | +15.0% | +20.8% | |
| Q1 2018 | -22.9% | -15.7% | -8.6% | |
| Q4 2017 | -4.0% | -11.3% | -17.4% | |
| Q3 2017 | -8.0% | -9.2% | -8.0% | |
| Q2 2017 | +7.1% | +6.0% | +9.3% | |
| Q1 2017 | -5.5% | -1.8% | +0.4% | |
| Q4 2016 | -5.0% | -5.1% | -16.4% | |
| Q3 2016 | +2.0% | +2.7% | +8.0% | |
| Q2 2016 | -5.0% | -2.3% | -6.7% | |
| Q1 2016 | +0.5% | — | — | |
| Q4 2015 | +11.2% | — | — | |
| Q3 2015 | +12.5% | — | — | |
| Q2 2015 | +3.2% | — | — | |
| Q1 2015 | -7.5% | — | — | |
| Q4 2014 | -10.7% | — | — | |
| Q3 2014 | +1.0% | — | — | |
| Q2 2014 | +4.1% | — | — | |
| Q1 2014 | +7.7% | — | — | |
| Q4 2013 | +26.9% | — | — | |
| Q3 2013 | +6.5% | — | — | |
| Q2 2013 | +21.9% | — | — | |
| Q1 2013 | -1.8% | — | — | |
| Q4 2012 | +16.6% | — | — | |
| Q3 2012 | -7.7% | — | — | |
| Q2 2012 | +24.4% | — | — | |
| Q1 2011 | +0.6% | — | — | |
| Q1 2012 | +2.8% | — | — | |
| Q4 2009 | +1.5% | — | — | |
| Q4 2011 | +1.5% | — | — | |
| Q3 2011 | +7.0% | — | — | |
| Q3 2010 | +7.0% | — | — | |
| Q2 2010 | -3.4% | — | — | |
| Q4 2010 | -3.4% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q1 2010 | -1.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro